Our phase I clinical trial in women with stage IV metastatic breast cancer (MBC) showed that multiple infusions of ATCs targeted with anti-CD3 × anti-HER2 BiAb induced the development of endogenous anti-tumor T-cell responses and induced a Th1 cytokine pattern (21, 26). This evidence concerns the gene ERBB2 and neoplasm.